Pulmongene (Hong Kong) Co., Ltd.

This is a phase 1b randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study of PMG1015 in idiopathic pulmonary fibrosis (IPF) subjects. This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PMG1015 after MAD.

评估PMG1015注射液在IPF受试者中多次给药及剂量递增的安全性和耐受性。

评估PMG1015注射液在健康志愿者中的安全性、耐受性、药代动力学和免疫原性。